Trial reportHIV medicine2026
Efficacy of dolutegravir/lamivudine in adults with HIV-1 and isolated reactive hepatitis B core antibody: Insights from Phase 3/3b study results.
Trial report in HIV medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- VOGUE: Noninferior Efficacy of Dolutegravir/Lamivudine Versus Bictegravir/Emtricitabine/Tenofovir Alafenamide in Adults With HIV-1 Naive to Treatment.Open forum infectious diseases · 2026Trial
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
objectivesAs two-drug HIV-1 antiretroviral therapy (ART) regimens become standard, data gaps remain concerning their safety and efficacy among people with isolated reactive hepatitis B core antibodies (anti-HBc). Here, we assessed the safety and efficacy of dolutegravir/lamivudine (DTG/3TC) versus three- or four-drug regimens (3DRs/4DRs) among people with HIV-1 and isolated reactive anti-HBc.
methodsData were evaluated from GEMINI-1, GEMINI-2, STAT, TANGO and SALSA at various time points, including Weeks 48, 96, 144 and 196. Participants had hepatitis B virus (HBV) exposure, isolated reactive anti-HBc serology, no HBV infection and were naive to ART (GEMINI-1/-2, STAT) or virologically suppressed before switching (TANGO, SALSA). All studies except STAT had a 3DR/4DR comparator.
resultsOf 2798 participants, 76 (DTG/3TC, n = 44; 3DR/4DR, n = 32) had isolated reactive anti-HBc. Across studies, no instances of HBV reactivation occurred, and liver chemistry elevations were infrequent and generally mild. Among those naive to ART at baseline and receiving DTG/3TC, 78% (18/23) achieved HIV-1 RNA <50 copies/mL at Week 144 in GEMINI-1/-2, and 60% (3/5) achieved HIV-1 RNA <50 copies/mL at Week 48 in STAT. Among participants with virologic suppression at baseline who switched from 3DR/4DR to DTG/3TC, none experienced HIV-1 RNA ≥50 copies/mL at the end of TANGO (Week 196) or SALSA (Week 48). HIV-1 suppression rates were comparable to those of 3DRs/4DRs.
conclusionsThis analysis provides new information about DTG/3TC treatment for people with HIV-1 and isolated reactive anti-HBc. There were high rates of HIV-1 suppression with DTG/3TC, no cases of HBV reactivation and no new safety signals identified.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.